NCT ID

NCT06465537

Title

A Clinical Study on CRISPR/Cas9 Instantaneous Gene Editing Therapy to Primary Open-angle Glaucoma With Elevated Intraocular Pressure and MYOC Gene Mutation

Sponsor

Shanghai BDgene Co., Ltd.

Status

RECRUITING

Phase

Phase 1/2

Condition raw

Primary Open Angle Glaucoma

Condition normalized

Primary Open Angle Glaucoma

Modality raw

gene therapy

Modality normalized

gene therapy

Target raw

MYOC gene mutation in patients with primary open-angle glaucoma (POAG) and elevated intraocular pressure (IOP). The intervention utilizes CRISPR/Cas9 technology to edit the MYOC gene, aiming to reduce IOP.

Target normalized

MYOC gene mutation in patients with primary open-angle glaucoma (POAG) and elevated intraocular pressure (IOP). The intervention utilizes CRISPR/Cas9 technology to edit the MYOC gene, aiming to reduce IOP.

Interventions

BD113vVLP